HydRegen 🇬🇧
Enzyme-based catalysts replacing precious-metal catalysts in chemical manufacturing
About HydRegen
HydRegen develops industrial biotechnology platforms that integrate biological processes into existing chemical manufacturing infrastructure, enabling significant cost savings and sustainability improvements. Their technologies serve as 'slot in' replacements for precious metal catalysts, facilitating the adoption of bio-based manufacturing while operating under milder biological conditions to enhance efficiency and reduce carbon emissions.
HydRegen is a UK-based company founded in 2020, now around 16 people. It has raised $8M in disclosed funding.
Founded by Holly Reeve (CEO & Co-founder; previously Reach plc; Cornell University), Sarah Cleary, Phd (Chief Scientific Officer, Co-Founder; previously Seventh Generation; University of Oxford).
Its investors also appear on FundFinder's most-active lists for Series A · Climate & Sustainability (53 funds), Series A · Healthcare & Wellbeing (54 funds), Series A · DeepTech (53 funds).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Series A (first close) · $8M · Oct 2026
- Clean Growth Fund — Clean Growth Fund is a £101m climate venture capital fund. · cheques £500k – £3M
- Future Planet — Future Planet Capital links global centres of innovation to opportunities capable of delivering breakthrough returns in the areas of Climate, Education, Health, Security and Sustainable Growth. · cheques £25k – £3M
- Oxford Technology — Oxford Capital is a technology venture capital investor based in London and Oxford. · cheques £50k – £1.5M
- UK Innovation & Science Seed Fund (UKI2S) — Evergreen, government-backed pre-seed+ fund managed by Future Planet Capital. · cheques up to £1.5M